EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series

Ian Nykaza iD, Andrea Moy, Stephen W Dusza, Alison Moskowitz iD, Gopa Iyer, Afsheen Iqbal, Robert Motzer iD, David H Ilson iD, Roisin E O'Cearbhaill, Rashek Kazi, Jennifer Defazio, Allison Gordon und 1 weitere

The Oncologist · 01.09.2025 · 30 (9)

DOI: 10.1093/oncolo/oyaf208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.07.2025. Verfasst von Ian Nykaza und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutaneous adverse events (irCAEs). Immune checkpoint inhibitor-related bullous pemphigoid (irBP), a severe, blistering irCAE occurs in 0.3%–1.5% of patients receiving ICI therapy. While systemic steroids can be effective, they are associated with significant toxicity and may mitigate ­immunotherapy antitumor efficacy. Consequently, steroid-sparing therapies are needed. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in non-ICI-related BP and appears promising for managing irBP.

Methods

We conducted a retrospective review of patients treated with dupilumab for irBP from April 2020 to April 2024. Clinical data, outcomes, and adverse events were assessed. Inhibitor-related bullous pemphigoid response was categorized as complete response (CR), partial response (PR), or no response (NR).

Results

In all, 17 patients (59% male, 82% non-Hispanic White; mean age 72.7 years) developed irBP while receiving PD-1/PDL-1 inhibitors. Sixteen patients (94%) received dupilumab for active irBP and one (6%) for prevention of recurrence. Dupilumab achieved CR of irBP for 12 patients (75%) and PR for 2 (12%) patients with active irBP. Ten (62%) achieved CR with dupilumab systemic monotherapy. Median time to first response was 19.5 days (range = 3–50). Most patients with CR (58%) failed prior oral corticosteroid therapy. The patient treated prophylactically experienced no irBP recurrence. Dupilumab was well-tolerated, with no adverse events.

Conclusions

Dupilumab is a promising steroid-sparing option for irBP, achieving initial response in under 20 days for most cases. Dupilumab is a valuable tool to manage this challenging irCAE while minimizing risk related to systemic steroid treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleFemaleAgedAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

ICIbullous pemphigoiddupilumabimmunotherapyoncodermatologytoxicity

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Department of Dermatology, Weill Cornell Medical College, New York, NY 10021, United States.
  • Department of Medicine, Weill Cornell Medical College, New York, NY 10021, United States.
  • Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.

ORCID-Profile: Ian Nykaza, Alison Moskowitz, Robert Motzer, David H Ilson, Alina Markova

Förderung

  • NCI NIH HHS

Zitieren

APA

Nykaza, I., Moy, A., Dusza, S. W., Moskowitz, A., Iyer, G., Iqbal, A., Motzer, R., Ilson, D. H., O'Cearbhaill, R. E., Kazi, R., Defazio, J., Gordon, A., & Markova, A. (2025). Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. The Oncologist, 30(9). https://doi.org/10.1093/oncolo/oyaf208

Vancouver

Nykaza I, Moy A, Dusza SW, Moskowitz A, Iyer G, Iqbal A, et al. Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. The Oncologist. 2025;30(9). doi:10.1093/oncolo/oyaf208

BibTeX
@article{Nykaza2025,
  author = {Nykaza, Ian and Moy, Andrea and Dusza, Stephen W and Moskowitz, Alison and Iyer, Gopa and Iqbal, Afsheen and Motzer, Robert and Ilson, David H and O'Cearbhaill, Roisin E and Kazi, Rashek and Defazio, Jennifer and Gordon, Allison and Markova, Alina},
  title = {Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {9},
  doi = {10.1093/oncolo/oyaf208}
}
Kostenlos starten →